
==== Front
World J Diabetes
WJD
World Journal of Diabetes
1948-9358
Baishideng Publishing Group Inc

jWJD.v15.i9.pg1837
10.4239/wjd.v15.i9.1837
94745
Editorial
MicroRNA-630: A potential guardian against inflammation in diabetic kidney disease
Al Madhoun A. MicroRNA-630 in DKD
Al Madhoun Ashraf Department of Genetics and Bioinformatics, Dasman Diabetes Institute, Dasman 15400, Kuwait. ashraf.madhoun@dasmainstitute.org

Author contributions: Al Madhoun A designed the overall concept, reviewed the literature, and wrote and edited the manuscript.

Supported by the Kuwait Foundation for the Advancement of Sciences and Dasman Diabetes Institute, Kuwait, No. RACB-2021-007.

Corresponding author: Ashraf Al Madhoun, PhD, Academic Research, Senior Scientist, Department of Genetics and Bioinformatics, Dasman Diabetes Institute, Jassim AlBahar Street, Dasman 15400, Kuwait. ashraf.madhoun@dasmainstitute.org

15 9 2024
15 9 2024
15 9 18371841
24 3 2024
20 5 2024
17 6 2024
©The Author(s) 2024. Published by Baishideng Publishing Group Inc. All rights reserved.
2024
https://creativecommons.org/licenses/by-nc/4.0/ This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial.
In this editorial, we comment on the article by Wu et al published “MicroRNA-630 alleviates inflammatory reactions in rats with diabetic kidney disease by targeting toll-like receptor 4”. Diabetic kidney disease (DKD) stands as a significant complication occurring from diabetes mellitus, which contributes substantially to the morbidity and mortality rates worldwide. Renal tubular epithelial cell da-mage, often accompanied by inflammatory responses and mesenchymal trans-differentiation, plays a pivotal role in the progression of DKD. Despite extensive research, the intricate molecular mechanisms underlying these processes remain to be determined. Wu et al remarkable work identifies microRNA-630 (miR-630) as an emerging potential regulator of cell migration, apoptosis, and autophagy, prompting investigation into its association with DKD pathogenesis. This study endeavors to elucidate the impact of miR-630 on TEC injury and the inflammatory response in DKD rats. The role of miR-630 in human DKD will be of interest for future studies.

Diabetic kidney disease
MicroRNA
MicroRNA-630
Toll-like receptor 4
Inflammation
==== Body
pmc Core Tip: Wu et al identified microRNA-630 as a promising candidate for the management of diabetic kidney disease, exerting its protective effects through the regulation of toll-like receptor 4-mediated inflammatory pathways. Further research elucidating the precise molecular mechanisms underlying microRNA-630’s actions and its therapeutic potential is warranted, with the ultimate goal of developing targeted interventions to alleviate the burden of diabetic kidney disease and improve patient outcomes.

INTRODUCTION

Diabetes mellitus is a significant global public health challenge with an increasing prevalence and associated morbidity and mortality. Diabetic kidney disease (DKD) is a serious complication of diabetes that significantly affects patients’ quality of life[1]. DKD is characterized by progressive damage to renal tubular epithelial cells (TECs), which serve as fundamental units responsible for orchestrating the reabsorption of crucial solutes and water within the kidney nephrons[2]. This damage occurs through multifaceted mechanisms intricately intertwined with the metabolic dysregulation characteristics of diabetes[3]. In this editorial, we comment on the article by Wu et al[4] published in the recent issue of the World Journal of Diabetes.

THE CULPRIT: RENAL TEC DAMAGE

Glucose and lipid metabolism dysregulation within TECs stemming from hyperglycemia- and insulin resistance-induced metabolic perturbations is a key pathological hallmark of DKD[5]. Elevated glucose levels within TECs trigger reactive oxygen species production, pro-inflammatory pathway activation, and intracellular signaling cascade dysregulation[6]. These metabolic stressors cause cellular dysfunction, impairing the ability of TECs to maintain a proper electrolyte balance and reabsorb essential nutrients[3].

The inflammatory response is a pivotal player in DKD progression. Hyperglycemia-induced oxidative stress and subsequent pro-inflammatory mediator release stimulate immune cell recruitment and activation within the renal interstitium[7]. Macrophages, lymphocytes, and other immune effectors infiltrate the kidney parenchyma and secrete excess cytokines, chemokines, and growth factors, which perpetuate tissue inflammation and injury[8]. This inflammatory microenvironment exacerbates functional TECs and accelerates renal damage progression. Pro-inflammatory cytokines such as tumor necrosis factor-alpha (TNF-α), interleukin-6 (IL-6), and IL-1β directly impair TEC function by disrupting cellular signaling pathways involved in ion transport, nutrient reabsorption, and cell survival[9]. Furthermore, they promote apoptosis and fibrosis within the renal tubules, further compromising kidney function[10,11].

THE ROLE OF MICRORNAS IN DKD

MicroRNAs (miRNAs) are pivotal regulators of intricate DKD pathogenesis and govern the diverse molecular me-chanisms underlying renal damage and dysfunction. These small non-coding RNAs exert their influence post-transcriptionally by binding to the 3′ untranslated region of target mRNAs and orchestrating their degradation or translational repression[12]. In DKD, miRNA is dysregulated in various renal cells, including podocytes[13], TECs[14], endothelial cells[15], and mesangial cells[16], where they intricately modulate key processes such as inflammation, fibrosis, apoptosis, and oxidative stress.

Upregulated miRNAs such as miR-21, miR-146a, and miR-192 impair inflammation in DKD by targeting anti-inflammatory or pro-resolving pathways[17], while downregulated miR-29 family members exert anti-inflammatory effects by inhibiting pro-fibrotic gene expression[18]. Renal fibrosis, a hallmark of DKD, is regulated by miRNAs such as miR-21, miR-192, the miR-200 family, and miR-433, which promote fibrosis by modulating extracellular matrix production and remodeling genes, whereas miR-29 family members counteract fibrosis by suppressing collagen and other fibrotic gene expression[19-21]. Additionally, dysregulated miRNAs, including miR-192, miR-200 family, and miR-216a, contribute to apoptosis and impair cell survival in DKD, whereas miR-21 and miR-29 family members exhibit protective effects by inhibiting apoptosis and enhancing cell survival[22]. Moreover, miRNAs play a pivotal role in regulating oxidative stress responses in DKD; miR-21, miR-200 family members, and miR-34a exacerbate oxidative stress by targeting antioxidant defense genes or activating oxidative stress pathways, whereas miR-29 family members exhibit antioxidant properties and protect against oxidative stress-induced renal injury[23,24]. Taken together, miRNA expression dysregulation intricately contributes to DKD pathogenesis by modulating critical molecular pathways involved in inflammation, fibrosis, apoptosis, and oxidative stress. Understanding the role of miRNAs in DKD pathophysiology holds promise for developing potential therapeutic strategies aimed at preventing or treating DKD.

TOLL-LIKE RECEPTOR 4 IN DKD

The toll-like receptor 4 (TLR4) belongs to the family of pattern recognition receptors that play a critical role in initiating both innate and adaptive immune responses[25]. TLRs are germline-encoded receptors functioning as pathogen recognition receptors and activated by exogenous pathogen-associated molecules and endogenous danger signals[26].

In DKD, TLR4 activation promotes oxidative stress, which is detrimental to disease progression. Conversely, TLR4 blockage reduces oxidative stress and potentially reverses hyperglycemia[27,28]. This activation is mediated by two primary pathways: The MyD88-dependent pathway, triggered at the cell surface and leading to the production of pro-inflammatory cytokines like TNF-α, IL-6, and IL-1β. Here, TLR4 dimerization recruits TIRAP and MyD88 adaptor proteins, which activate IL-1 receptor-associated kinases and ultimately drive the production of these inflammatory mediators via nuclear factor-kappaB and AP-1 transcription factors[29].

THE ROLE OF MIR-630 AND TLR4 IN DKD

Studies suggest that miR-630 might be involved in cellular processes such as migration, apoptosis, and autophagy[30,31]; however, its role in DKD and the underlying mechanisms were unclear before the current investigation. Wu et al[4] used a well-established rat model of streptozotocin-induced DKD, a drug that damages insulin-producing cells. The rats were then divided into groups, and some received treatment to overexpress miR-630. After a set period, various parameters were evaluated to understand how miR-630 overexpression affects DKD course. Initial observations confirmed that miR-630 expression significantly decreased in the DKD rat kidney tissues compared to that in healthy control kidney tissues. These findings suggest that reduced miR-630 levels may be associated with DKD progression.

The researchers then used bioinformatic tools to predict the potential target genes of miR-630 and identified TLR4 as a possible candidate as it plays a crucial role in inflammatory responses. Further investigation using cell cultures confirmed the link between miR-630 and TLR4. MiR-630 overexpression decreased TLR4 expression, suggesting that miR-630 may regulate TLR4 expression and potentially reduce inflammation.

MIR-630 COMBATS INFLAMMATION AND PROTECTS TECS

Interestingly, the level of key inflammatory markers, including TNF-α, IL-1β, and IL-6, were significantly reduced in the miR-630-overexpressed group compared to that in the control group with DKD. Moreover, the expression of E-cadherin protein, a quintessential marker indicating robust TEC health, was preserved in the miR-630-overexpressed rats, which indicates the potential mitigation of TEC injury and dysfunction. Furthermore, the expression of proteins associated with fibrosis also decreased, further emphasizing the protective effects of miR-630. This multifaceted response suggests that miR-630 not only attenuates inflammation, but also protects against fibrotic progression and cellular transformation, potentially delaying DKD pathogenesis.

IN VIVO EVIDENCE STRENGTHENS THE CASE

Subsequent investigations employing an in vivo model provided robust validation of the initial observations. The renal function improved, and inflammatory marker levels significantly reduced in the rats with DKD treated with an miR-630 agonist, indicating substantial kidney inflammation suppression. Moreover, histopathological assessments revealed diminished renal damage in the miR-630 agonist-treated group compared to that in the untreated DKD control cohort.

FUTURE DIRECTIONS: FROM BENCH TO BEDSIDE

Owing to the established role of TLR4 in DKD pathogenesis, researchers are actively exploring therapeutic strategies to regulate its expression. These potential modulators encompass a diverse range of tools, including antibodies[32], small-molecule inhibitors[33,34], peptides[35], miRNAs[36], nanoparticles[37], lipid A analogs[38], and natural product de-rivatives[39], which have been best reviewed by Ain et al[40] and Zaffaroni and Peri[41]. Additionally, anti-inflammatory agents targeting the TLR4 downstream signaling pathway, particularly nuclear factor-kappaB inhibitors, demonstrate promise in alleviating kidney damage[42].

Although existing therapies offer benefits by reducing inflammation and protecting the kidneys, they often lack specificity. The current study highlights miR-630 as a promising therapeutic target specifically for DKD owing to its ability to regulate TLR4, suggesting a novel and targeted approach for this debilitating diabetic complication. However, further research is necessary to elucidate its tissue specificity and the precise mechanisms underlying its effects as well as translate its overexpression into a safe and effective therapeutic strategy for patients with DKD.

CONCLUSION

DKD poses a severe health burden. Damage to TECs through hyperglycemia-induced oxidative stress, inflammation, and metabolic dysregulation underpins DKD progression. miRNAs emerge as key regulatory molecules, modulating various pathogenic processes including inflammation and oxidative stress. Among these, miR-630 shows significant promise by targeting TLR4, thereby mitigating inflammation and protecting TECs from injury. Wu et al’s study underscores miR-630’s therapeutic potential, demonstrating its ability to reduce inflammatory markers and improve renal function in DKD models[4]. The translation of these findings from bench to bedside could herald a new era of targeted therapies for DKD, emphasizing the need for further research to ensure tissue specificity and therapeutic safety. As our understanding of miRNAs and their interactions with molecular pathways deepens, miR-630 stands out as a promising candidate in the quest to alleviate the burden of DKD and enhance patient outcomes.

Conflict-of-interest statement: The author reports no relevant conflicts of interest for this article.

Provenance and peer review: Invited article; Externally peer reviewed.

Peer-review model: Single blind

Specialty type: Endocrinology and metabolism

Country of origin: Kuwait

Peer-review report’s classification

Scientific Quality: Grade A, Grade C

Novelty: Grade A, Grade B

Creativity or Innovation: Grade A, Grade B

Scientific Significance: Grade A, Grade B

P-Reviewer: Li XD; Liu W S-Editor: Wang JJ L-Editor: A P-Editor: Chen YX
==== Refs
1 Thomas MC Brownlee M Susztak K Sharma K Jandeleit-Dahm KA Zoungas S Rossing P Groop PH Cooper ME Diabetic kidney disease Nat Rev Dis Primers 2015 1 15018 27188921
2 Zhou X Xu C Dong J Liao L Role of renal tubular programed cell death in diabetic kidney disease Diabetes Metab Res Rev 2023 39 e3596 36401596
3 Wang Y Jin M Cheng CK Li Q Tubular injury in diabetic kidney disease: molecular mechanisms and potential therapeutic perspectives Front Endocrinol (Lausanne) 2023 14 1238927 37600689
4 Wu QS Zheng DN Ji C Qian H Jin J He Q MicroRNA-630 alleviates inflammatory reactions in rats with diabetic kidney disease by targeting toll-like receptor 4 World J Diabetes 2024 15 488 501 38591087
5 Su W Cao R He YC Guan YF Ruan XZ Crosstalk of Hyperglycemia and Dyslipidemia in Diabetic Kidney Disease Kidney Dis (Basel) 2017 3 171 180 29344511
6 Wu Y Zhang M Liu R Zhao C Oxidative Stress-Activated NHE1 Is Involved in High Glucose-Induced Apoptosis in Renal Tubular Epithelial Cells Yonsei Med J 2016 57 1252 1259 27401659
7 Yang M Zhang C The role of innate immunity in diabetic nephropathy and their therapeutic consequences J Pharm Anal 2024 14 39 51 38352948
8 Cantero-Navarro E Rayego-Mateos S Orejudo M Tejedor-Santamaria L Tejera-Muñoz A Sanz AB Marquez-Exposito L Marchant V Santos-Sanchez L Egido J Ortiz A Bellon T Rodrigues-Diez RR Ruiz-Ortega M Role of Macrophages and Related Cytokines in Kidney Disease Front Med (Lausanne) 2021 8 688060 34307414
9 Donate-Correa J Martín-Núñez E Muros-de-Fuentes M Mora-Fernández C Navarro-González JF Inflammatory cytokines in diabetic nephropathy J Diabetes Res 2015 2015 948417 25785280
10 Su H Lei CT Zhang C Interleukin-6 Signaling Pathway and Its Role in Kidney Disease: An Update Front Immunol 2017 8 405 28484449
11 Kadatane SP Satariano M Massey M Mongan K Raina R The Role of Inflammation in CKD Cells 2023 12
12 O'Brien J Hayder H Zayed Y Peng C Overview of MicroRNA Biogenesis, Mechanisms of Actions, and Circulation Front Endocrinol (Lausanne) 2018 9 402 30123182
13 Liu F Chen J Luo C Meng X Pathogenic Role of MicroRNA Dysregulation in Podocytopathies Front Physiol 2022 13 948094 35845986
14 Chang J Yan J Li X Liu N Zheng R Zhong Y Update on the Mechanisms of Tubular Cell Injury in Diabetic Kidney Disease Front Med (Lausanne) 2021 8 661076 33859992
15 Chen SJ Lv LL Liu BC Tang RN Crosstalk between tubular epithelial cells and glomerular endothelial cells in diabetic kidney disease Cell Prolif 2020 53 e12763 31925859
16 Kato M Arce L Wang M Putta S Lanting L Natarajan R A microRNA circuit mediates transforming growth factor-β1 autoregulation in renal glomerular mesangial cells Kidney Int 2011 80 358 368 21389977
17 Das K Rao LVM The Role of microRNAs in Inflammation Int J Mol Sci 2022 23
18 Qin W Chung AC Huang XR Meng XM Hui DS Yu CM Sung JJ Lan HY TGF-β/Smad3 signaling promotes renal fibrosis by inhibiting miR-29 J Am Soc Nephrol 2011 22 1462 1474 21784902
19 Chung AC Lan HY MicroRNAs in renal fibrosis Front Physiol 2015 6 50 25750628
20 Cao Q Chen XM Huang C Pollock CA MicroRNA as novel biomarkers and therapeutic targets in diabetic kidney disease: An update FASEB Bioadv 2019 1 375 388 32123840
21 Sakuma H Hagiwara S Kantharidis P Gohda T Suzuki Y Potential Targeting of Renal Fibrosis in Diabetic Kidney Disease Using MicroRNAs Front Pharmacol 2020 11 587689 33364960
22 Szostak J Gorący A Durys D Dec P Modrzejewski A Pawlik A The Role of MicroRNA in the Pathogenesis of Diabetic Nephropathy Int J Mol Sci 2023 24
23 Dhas Y Arshad N Biswas N Jones LD Ashili S MicroRNA-21 Silencing in Diabetic Nephropathy: Insights on Therapeutic Strategies Biomedicines 2023 11
24 Tang J Yao D Yan H Chen X Wang L Zhan H The Role of MicroRNAs in the Pathogenesis of Diabetic Nephropathy Int J Endocrinol 2019 2019 8719060 31885563
25 Molteni M Gemma S Rossetti C The Role of Toll-Like Receptor 4 in Infectious and Noninfectious Inflammation Mediators Inflamm 2016 2016 6978936 27293318
26 Liu T Gao YJ Ji RR Emerging role of Toll-like receptors in the control of pain and itch Neurosci Bull 2012 28 131 144 22466124
27 Karpova T de Oliveira AA Naas H Priviero F Nunes KP Blockade of Toll-like receptor 4 (TLR4) reduces oxidative stress and restores phospho-ERK1/2 levels in Leydig cells exposed to high glucose Life Sci 2020 245 117365 32001267
28 Panchapakesan U Pollock C The role of toll-like receptors in diabetic kidney disease Curr Opin Nephrol Hypertens 2018 27 30 34 29059081
29 Wang K Huang H Zhan Q Ding H Li Y Toll-like receptors in health and disease MedComm (2020) 2024 5 e549 38685971
30 Simiene J Dabkeviciene D Stanciute D Prokarenkaite R Jablonskiene V Askinis R Normantaite K Cicenas S Suziedelis K Potential of miR-181a-5p and miR-630 as clinical biomarkers in NSCLC BMC Cancer 2023 23 857 37697308
31 Huang Y Guerrero-Preston R Ratovitski EA Phospho-ΔNp63α-dependent regulation of autophagic signaling through transcription and micro-RNA modulation Cell Cycle 2012 11 1247 1259 22356768
32 Monnet E Lapeyre G Poelgeest EV Jacqmin P Graaf K Reijers J Moerland M Burggraaf J Min C Evidence of NI-0101 pharmacological activity, an anti-TLR4 antibody, in a randomized phase I dose escalation study in healthy volunteers receiving LPS Clin Pharmacol Ther 2017 101 200 208 27706798
33 Xu Y Chen S Cao Y Zhou P Chen Z Cheng K Discovery of novel small molecule TLR4 inhibitors as potent anti-inflammatory agents Eur J Med Chem 2018 154 253 266 29807331
34 Neal MD Jia H Eyer B Good M Guerriero CJ Sodhi CP Afrazi A Prindle T Jr Ma C Branca M Ozolek J Brodsky JL Wipf P Hackam DJ Discovery and validation of a new class of small molecule Toll-like receptor 4 (TLR4) inhibitors PLoS One 2013 8 e65779 23776545
35 Michaeli A Mezan S Kühbacher A Finkelmeier D Elias M Zatsepin M Reed SG Duthie MS Rupp S Lerner I Burger-Kentischer A Computationally Designed Bispecific MD2/CD14 Binding Peptides Show TLR4 Agonist Activity J Immunol 2018 201 3383 3391 30348734
36 Kaur P Kotru S Singh S Munshi A Role of miRNAs in diabetic neuropathy: mechanisms and possible interventions Mol Neurobiol 2022 59 1836 1849 35023058
37 Babazada H Yanamoto S Hashida M Yamashita F Binding and structure-kinetic relationship analysis of selective TLR4-targeted immunosuppressive self-assembling heparin nanoparticles Int J Pharm 2018 552 76 83 30253213
38 Arias MA Van Roey GA Tregoning JS Moutaftsi M Coler RN Windish HP Reed SG Carter D Shattock RJ Glucopyranosyl Lipid Adjuvant (GLA), a Synthetic TLR4 agonist, promotes potent systemic and mucosal responses to intranasal immunization with HIVgp140 PLoS One 2012 7 e41144 22829921
39 Molteni M Bosi A Rossetti C Natural Products with Toll-Like Receptor 4 Antagonist Activity Int J Inflam 2018 2018 2859135 29686833
40 Ain QU Batool M Choi S TLR4-Targeting Therapeutics: Structural Basis and Computer-Aided Drug Discovery Approaches Molecules 2020 25
41 Zaffaroni L Peri F Recent advances on Toll-like receptor 4 modulation: new therapeutic perspectives Future Med Chem 2018 10 461 476 29380635
42 Rezaee A Rahmanian P Nemati A Sohrabifard F Karimi F Elahinia A Ranjbarpazuki A Lashkarbolouki R Dezfulian S Zandieh MA Salimimoghadam S Nabavi N Rashidi M Taheriazam A Hashemi M Hushmandi K NF-ĸB axis in diabetic neuropathy, cardiomyopathy and nephropathy: A roadmap from molecular intervention to therapeutic strategies Heliyon 2024 10 e29871 38707342
